The organization and the assembly of the fibronectin matrix is known to regulate the progression of cells through the cell cycle. As the fibronectin matrix undergoes continual remodeling in vivo, it provides a potential target for therapies (i.e., anti-metastatic or anti-angiogenic) aimed at controlling cell growth. The molecular mechanisms by which fibronectin matrix organization regulates cell growth are poorly understood. During the previous funding period we have shown that anastellin, an anti-angiogenic peptide derived from the first Type III module of fibronectin, induces remodeling of the fibronectin matrix and completely inhibits the growth of human microvessel endothelial cells. We have also shown that the remodeling of the fibronectin matrix is associated with changes in adhesion, but not growth factor, regulation of ERK pathways necessary for the expression of cyclin D and cyclin A. During the next funding period, we will evaluate the hypothesis that anastellin-induced fibronectin matrix remodeling affects integrin and LPA dependent regulation of FAK/Rho pathways necessary for ERK activity. Studies described in AIM 1 will use neutralizing antibodies, peptide agonists and antagonists, and various null cell lines to address the role of EDA+ fibronectin, the alpha4beta1 fibronectin integrin and heparan sulfate proteogiycans in the regulation of MAP kinase activity. Studies in AIM 2 will evaluate the effect of anastellin on integrin regulation of ERK. The effect of anastellin on the kinetics and extent of Rho and FAK activation will be evaluated using Western Blots and Rho pull-down assays. The ability of active forms of Rho and FAK to rescue integrin signaling to ERK in the presence of anastellin will be assessed by using adenoviral vectors expressing constitutively active forms of FAK and Rho.
In AIM 3, Western blotting, pharmacological inhibitors, and dominant/negative adenoviral constructs will be used to define the role of the Ras/Raf1 MEK1 pathway in the activation of ERK by LPA. Activation of ERK by LPA will be assessed by Western blot, nuclear localization and activation of transcription factors.
In AIM 4, the role of growth factor transactivation and Rho/Rho kinase in the activation of ERK by LPA will be assessed using pharmacological inhibitors of tyrosine kinases and adenoviral vectors containing dominant/negative Rho and Rac constructs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ONC-Q (01))
Program Officer
Sussman, Daniel J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albany Medical College
Schools of Medicine
United States
Zip Code
Shinde, Arti V; Kelsh, Rhiannon; Peters, John H et al. (2015) The ?4?1 integrin and the EDA domain of fibronectin regulate a profibrotic phenotype in dermal fibroblasts. Matrix Biol 41:26-35
You, Ran; Zheng, Mingzhe; McKeown-Longo, Paula J (2010) The first type III repeat in fibronectin activates an inflammatory pathway in dermal fibroblasts. J Biol Chem 285:36255-9
Ambesi, Anthony; McKeown-Longo, Paula J (2009) Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling. Mol Cancer Res 7:255-65
You, Ran; Klein, R Matthew; Zheng, Mingzhe et al. (2009) Regulation of p38 MAP kinase by anastellin is independent of anastellin's effect on matrix fibronectin. Matrix Biol 28:101-9
Neskey, David M; Ambesi, Anthony; Pumiglia, Kevin M et al. (2008) Endostatin and anastellin inhibit distinct aspects of the angiogenic process. J Exp Clin Cancer Res 27:61
Meckmongkol, Teerin T; Harmon, Robert; McKeown-Longo, Paula et al. (2007) The fibronectin synergy site modulates TGF-beta-dependent fibroblast contraction. Biochem Biophys Res Commun 360:709-14
Zheng, Mingzhe; Ambesi, Anthony; Yu, Lin et al. (2007) Quantification of fibronectin matrix assembly sites using a novel ELISA assay. Matrix Biol 26:330-3
Zheng, Mingzhe; McKeown-Longo, Paula J (2006) Cell adhesion regulates Ser/Thr phosphorylation and proteasomal degradation of HEF1. J Cell Sci 119:96-103
Ambesi, Anthony; Klein, R Matthew; Pumiglia, Kevin M et al. (2005) Anastellin, a fragment of the first type III repeat of fibronectin, inhibits extracellular signal-regulated kinase and causes G(1) arrest in human microvessel endothelial cells. Cancer Res 65:148-56
Monaghan, Elizabeth; Gueorguiev, Volodia; Wilkins-Port, Cynthia et al. (2004) The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts. J Biol Chem 279:1400-7

Showing the most recent 10 out of 20 publications